Category: HPV

January – Cervical Cancer Awareness Month

January is internationally dedicated to raising awareness about cervical cancer. Known as Cervical Cancer Awareness Month, it aims to highlight the importance of prevention, early detection, and vaccination against the human papillomavirus (HPV), which is responsible for nearly all cases of the disease.

Cervical cancer remains a major public health issue worldwide. According to the World Health Organization, approximately 660,000 new cases are diagnosed globally each year, and more than 350,000 women lose their lives to the disease. It is among the most common cancers affecting women, particularly in regions where access to preventive screening and vaccination is limited. At the same time, it is one of the few cancers that can largely be prevented through organized prevention and early detection programmes.

In Greece, available data indicate that around 700 new cases of cervical cancer are diagnosed annually, while more than 280 deaths are attributed to the disease each year. The estimated incidence is approximately 8 cases per 100,000 women. Although this places Greece close to the European average, it also highlights the need for further improvement in prevention and early diagnosis.

Cervical cancer is closely linked to chronic infection with human papillomavirus (HPV), a very common virus transmitted mainly through sexual contact.

HPV vaccination, combined with regular gynaecological screening through Pap tests and HPV tests, can significantly reduce the development of precancerous lesions and cervical cancer. In this context, the World Health Organization has set the goal of eliminating cervical cancer as a public health problem by 2030, through high vaccination coverage, universal screening, and timely treatment.

January serves as an important reminder that information and prevention save lives. Open discussion around women’s health, free from fear and stigma, empowers women to take care of themselves and to claim prevention as a fundamental right.

Special emphasis should be placed on the systematic education of younger generations, as prevention begins long before any symptoms appear. Access to reliable information, preventive screening services, and vaccination programmes is a key factor in reducing health inequalities and protecting future generations.

At KAPA3, we believe that information and prevention are core pillars of care and empowerment. Through the dissemination of reliable information and the support of initiatives that promote public health, we stand alongside every woman who needs knowledge, prevention, and timely care.

Because cervical cancer can be prevented, we encourage everyone to take action. Give a meaningful gift to the women you care about: daughters, sisters, mothers, friends, partners, spouses. Talk openly about women’s health, share information, support initiatives, challenge taboos, and promote early diagnostic screening.

Information and open dialogue are the strongest tools we have.

Sources:

World Health Organization (WHO)
Cervical cancer – Fact sheet

WHO – Global strategy to accelerate the elimination of cervical cancer

International Agency for Research on Cancer (IARC / WHO)
Cervical Cancer Awareness Month

ICO / IARC HPV Information Centre – Greece Factsheet

Ministry of Health – National Immunization Programme

Hellenic National Public Health Organization (EODY)
HPV and cervical cancer

Text/adaptation: Ifiyenia Anastasiou for Kapa3

EGFR: An “Old Target” Gaining New Life in Cancer Research

When science moves forward step by step

Progress in oncology does not always come with dramatic announcements. Often, it is found in studies that show small but meaningful steps. One such case is a recent review in JAMA Oncology exploring new targeted therapies for head and neck cancer — a type of cancer often linked to smoking, alcohol consumption, or HPV infection. At Kapa3, we closely follow these developments to keep patients and their families responsibly informed,

Researchers focused on a protein called EGFR (Epidermal Growth Factor Receptor). Approximately 90% of patients with this type of cancer show overexpression of the protein, making it an attractive target for therapy. In the past, drugs such as cetuximab attempted to “block” EGFR activity, but results were limited. Patients experienced modest improvements without a significant increase in survival.

The new generation of research goes a step further. Combination therapies are being explored, such as targeting EGFR alongside immunotherapy (e.g., pembrolizumab), which strengthens the body’s defense against cancer cells. In early studies, this combination showed response rates around 45% and a median survival of approximately 18 months in patients for whom previous treatments had failed — results that, while not dramatic, are considered encouraging for this disease.

Scientists now understand that the success of targeted therapy depends on multiple factors. In many patients, cancer cells eventually develop resistance, “learning” to bypass the drug’s effect. In addition, cancers linked to HPV appear to behave differently from those that are not, opening new avenues for more personalized approaches.

Research is also focusing on identifying biomarkers — molecular indicators that can show which patients are most likely to benefit from a particular therapy. If these tools prove reliable, they could lead to more targeted, effective, and safer treatments in the future.

At the same time, newer forms of drugs are being tested, such as bispecific antibodies and antibody–drug conjugates, which aim to target cancer cells with greater precision. All of these efforts are still in early clinical trial stages, aiming to improve efficacy and reduce side effects.

The key message of this research is not that a “new drug that beats cancer” has been found, but that science continues to search, test, and learn. Every small step, every percentage of improvement, every new idea paves the way for future progress.

For people living with cancer — and their families — hope lies not only in major breakthroughs and new treatments but also in the certainty that thousands of researchers around the world are tirelessly working to make each next step a little closer to life. Because in science, as in life, progress is often measured not in leaps but in steady, human steps. At Kapa3, we are committed to sharing this news in a clear and useful way for everyone.

Read the review here

Sources:

Hwang W. et al. “Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.” JAMA Oncology (2025).
World Health Organization – Cancer Research Updates

Text/adaptation: Ifiyenia for Kapa3